Shots:
- Rezubio has completed dosing of the first cohort in its P-I trial of RZ-520, following US FDA & Chinese NMPA clearances to assess its safety, tolerability, PK & PD in healthy volunteers
- RZ-520 is a clinical-stage asset developed using Rezubio’s MADD platform, with preclinical studies showing robust efficacy, superior safety & negligible systemic exposure across multiple disease models
- MADD platform engineers tissue-targeted therapies with prolonged local residence & optimized PK, enabling differentiated treatments against cell-surface proteins in the respiratory and GI tracts
Ref: Globenewswire | Image: Rezubio | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
